Skip to content
  • About GRP
    • Why Choose Us
    • Leadership
    • Brochure
    • Careers
  • Countries
    • Canada’s Health Canada
    • United States’ FDA
    • Brazil
    • Mexico’s COFEPRIS
    • Europe’s EMA
    • Australia
    • China
    • Japan’s PMDA
    • Korea’s Ministry of Food and Drug Safety (MFDS)
    • Taiwan’s Food and Drug Administration (TFDA)
    • Singapore’s HSA
    • India’s CDSCO

    North America

    Canada

    United States of America

    Latin AMerica

    Brazil

    Mexico

    Europe

    European Union

    Australia

    Australia

    Asia

    China

    Japan

    South Korea

    Taiwan

    Singapore

    India

  • Services

    Medical Devices

    • Authorized Local Agent
    • Regulatory Intelligence
    • Regulatory Strategy
    • Regulatory Affairs
    • Product Registration
    • Medical Writing
    • Health Authority Consultation
    • Clinical

    Pharmaceuticals

    • Authorized Local Agent
    • Regulatory Intelligence
    • Regulatory Strategy
    • Regulatory Affairs
    • Product Registration
    • Regulatory Operations
    • Health Authority Consultation

    Nutraceuticals / Food Supplements

    • Authorized Local Agent
    • Regulatory Intelligence
    • Regulatory Affairs
    • Regulatory Strategy
    • Verification of Nutrient Claims
    • Verification of Health Claims

    Cosmetics & Personal Care Products

    • Authorized Local Agent
    • Regulatory Intelligence
    • Regulatory Affairs
    • Regulatory Strategy
    • Cosmetic Packaging and Labeling Review
    • Product Classification and Formulation Review

    Pharmacovigilance

    • Overview
    • GRP Pharmacoviglance Services

    Quality

    • Preparation for FDA Inspections
    • GMP Mockup Quality Audits
    • ISO 13485 Quality Audits
    • GCP Audits
    • cGTP Audits
    • GAP Analysis Audits
    • Foreign Manufacture Accreditation (FMA)
    • QA SOPs Development
  • Resource Center
    • Blog
    • Market Access Special Programs
    • Press Releases
    • White Papers
    • Case Studies
    • Videos
    • Presentations
    • Brochure
  • RI Platform
    • Japan Regulatory Intelligence (RI)
    • China (NMPA) Regulatory Intelligence
    • Brazil
    • Mexico Regulatory Intelligence (RI)
    • USA Regulatory Intelligence (RI)

    Japan

    • Health Authority
    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements

    China

    • Health Authority
    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements

    Brazil

    • Health Authority
    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements

    Mexico

    • Health Authority
    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements

    USA

    • Medical Device
    • Pharmaceuticals
    • Clinical Trials
    • Cosmetics
    • Food Supplements
  • Contact Us
  • About GRP
    • Why Choose Us
    • Leadership
    • Brochure
    • Careers
  • Countries
    • Canada’s Health Canada
    • United States’ FDA
    • Brazil
    • Mexico’s COFEPRIS
    • Europe’s EMA
    • Australia
    • China
    • Japan’s PMDA
    • Korea’s Ministry of Food and Drug Safety (MFDS)
    • Taiwan’s Food and Drug Administration (TFDA)
    • Singapore’s HSA
    • India’s CDSCO
  • Services
  • Resource Center
    • Blog
    • Market Access Special Programs
    • Press Releases
    • White Papers
    • Case Studies
    • Videos
    • Presentations
    • Brochure
  • RI Platform
    • Japan Regulatory Intelligence (RI)
    • China (NMPA) Regulatory Intelligence
    • Brazil
    • Mexico Regulatory Intelligence (RI)
    • USA Regulatory Intelligence (RI)
  • Contact Us
  • About GRP
    • Why Choose Us
    • Leadership
    • Brochure
    • Careers
  • Countries
    • Canada’s Health Canada
    • United States’ FDA
    • Brazil
    • Mexico’s COFEPRIS
    • Europe’s EMA
    • Australia
    • China
    • Japan’s PMDA
    • Korea’s Ministry of Food and Drug Safety (MFDS)
    • Taiwan’s Food and Drug Administration (TFDA)
    • Singapore’s HSA
    • India’s CDSCO
  • Services
  • Resource Center
    • Blog
    • Market Access Special Programs
    • Press Releases
    • White Papers
    • Case Studies
    • Videos
    • Presentations
    • Brochure
  • RI Platform
    • Japan Regulatory Intelligence (RI)
    • China (NMPA) Regulatory Intelligence
    • Brazil
    • Mexico Regulatory Intelligence (RI)
    • USA Regulatory Intelligence (RI)
  • Contact Us

Category: blogs

ANVISA NEW REGULATION FOR POST-APPROVAL CHANGES TO MEDICAL DEVICES: RDC 340/2020

On March 3, 2020, Anvisa published a new regulation “RDC 340/2020” that classifies the changes made to approved medical devices in Brazil, into three categories based on the level of risk .

FDA New Policy on Emergency Use Authorization (EUA) of In Vitro Diagnostics of Coronavirus

EUA of COIVD-19

On February 2020, FDA issued a Policy that allows CLIA certified high-complexity testing laboratories to use their validated diagnostic tests to detect the SARS-CoV-2 virus in specimen while they are preparing for EUA submission to FDA.

NMPA Emergency Approval of Imported Medical Devices in China: What this means for Foreign Manufacturers

The Coronavirus outbreak in China has led to an extraordinary demand of some medical devices. The NMPA (Chinese health authority) started granting emergency approval to some imported medical device, provided that they meet certain regulatory and quality standards.

FDA Draft Guidance on Performance Criteria for Safety and Performance Based Pathway for Soft Daily Wear Contact Lenses

On March 4, 2020, US FDA published a new draft guidance to allow manufacturers of eligible daily wear soft (hydrophilic) contact lenses to use new performance criteria pathway to support substantial equivalence instead of a direct comparison of the performance of their device to that of a predicate device during 510(K0 submission

China’s Communist Party held a meeting on March 4 to study the current state of Coronavirus in China.

The Standing Committee of the Political Bureau of the Central Committee of the Communist Party of China held a meeting on March 4 which was presided over by General Secretary Xi Jinping to study the current priorities for the prevention and control of the novel coronavirus epidemic and the stabilization of economic and social operations

The FDA Prepares for the Fourteenth Annual Meeting International Cooperation on Cosmetics Regulation.

meeting with FDA

The FDA announces on March 3rd that they hold a public meeting regarding the 14th International Cooperation on Cosmetics Regulation (ICCR)- to be held on April 14, 2020.

Singapore announces facilitated Importation of Hand Sanitizers, Masks, Thermometers and Protective Gear

Since January 31, 2020, importers of the certain medical devices do not require an importer’s license from Singapore’s Health Science Authority (HSA).

PMDA Approach to Artificial Intelligence (AI) based Medical Devices

PMDA Approach to Artificial Intelligence (AI) based Medical Devices

PMDA has adapted emerging technologies such as AI based medical devices and has reviewed the registration process to make it more efficient.

Mexico Prohibits the importation of electronic cigarettes by presidential decree (02/2020)

Mexico Prohibits the importation of electronic cigarettes by presidential decree.

The Government of Mexico, concerned about the health of Mexicans, Prohibits the importation of electronic cigarettes by presidential decree.

The FDA publishes Guidance for Nutrition and Supplements Facts Labels for Small Entity Compliance

Nutrition Labeling Fact, dietary supplement Labeling and Packaging requirments, FDA, small entity

FDA publishes guidance for final rule intended to help small entities comply with the nutrition facts labeling requirements

The FDA publishes FY 2019 GDUFA Science and Research Report

THE FDA PUBLISHES FY 2019 GDUFA SCIENCE AND RESEARCH REPORT

The FDA’s FY 2019 GDUFA report provides detailed results for 13 areas of focus, including research activities and comprehensive lists of grants and contracts.

Anvisa’s Call Notice 2/2020 : Similar Drug Notice

Call Anvisa Call Notice 02-2020 Similar Drugs- Specific Subject Code

On Thursday (1/30), Anvisa published Call Notice 2/2020 , aimed at requesting information on similar drugs registered in Brazil.

← Previous
Next →

ABOUT GRP GROUP

  • About US
  • Leadership
  • Why Choose Us

Useful Links

  • Contact Us
  • Brochures
  • Resource Center

GRP Headquarters (USA)

303 Wyman Street, Suite 300
Waltham, MA. 02451, USA
Tel : (+1 ) 781 - 672 -4200
Info@globalregulatorypartners.com

GRP Group Offices

  • GRP USA
  • GRP Japan
  • GRP China
  • GRP Korea
  • GRP Brazil
  • GRP Mexico

Follow Us on Social Media

Twitter Youtube Linkedin
  • Privacy Policy
  • Terms & Conditions
  • Cookies Policy
  • Other Policies

Copyright ©2023 Global Regulatory Partners

Contact Us!